Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
J Clin Oncol. 2021 Jun 20;39(18):1959-1970. doi: 10.1200/JCO.20.03175. Epub 2021 Mar 19.
J Clin Oncol. 2021.
PMID: 33739857
Free PMC article.
Clinical Trial.
Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.
Bröske AE, Korfi K, Belousov A, Wilson S, Ooi CH, Bolen CR, Canamero M, Alcaide EG, James I, Piccione EC, Carlile DJ, Dimier N, Umaña P, Bacac M, Weisser M, Dickinson M.
Bröske AE, et al.
Blood Adv. 2022 Feb 8;6(3):1025-1037. doi: 10.1182/bloodadvances.2021005954.
Blood Adv. 2022.
PMID: 34941996
Free PMC article.
Item in Clipboard
Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies.
Dziadek S, Kraxner A, Cheng WY, Ou Yang TH, Flores M, Theiss N, Tsao TS, Andersson E, Harring SV, Bröske AE, Ceppi M, Teichgräber V, Charo J.
Dziadek S, et al. Among authors: broske ae.
Front Immunol. 2024 Mar 15;15:1352615. doi: 10.3389/fimmu.2024.1352615. eCollection 2024.
Front Immunol. 2024.
PMID: 38558814
Free PMC article.
Item in Clipboard
Cite
Cite